DarioHealth Corp. (DRIO) Getting Somewhat Positive Media Coverage, Accern Reports

Media stories about DarioHealth Corp. (NASDAQ:DRIO) have trended somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. DarioHealth Corp. earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave media headlines about the company an impact score of 47.1129177624281 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

DarioHealth Corp. (DRIO) traded down 0.2541% during trading on Tuesday, hitting $1.8453. The stock had a trading volume of 6,787 shares. The firm has a 50 day moving average price of $1.83 and a 200-day moving average price of $1.83. DarioHealth Corp. has a 1-year low of $1.69 and a 1-year high of $4.70. The firm’s market capitalization is $18.00 million.

DarioHealth Corp. (NASDAQ:DRIO) last released its quarterly earnings results on Monday, August 14th. The company reported ($0.43) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.13). The business had revenue of $1.21 million during the quarter. DarioHealth Corp. had a negative return on equity of 626.32% and a negative net margin of 206.95%. On average, equities research analysts expect that DarioHealth Corp. will post ($0.62) EPS for the current year.

Separately, Aegis began coverage on DarioHealth Corp. in a research report on Tuesday, August 29th. They set a “buy” rating and a $3.50 price target on the stock.

COPYRIGHT VIOLATION WARNING: This piece was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://ledgergazette.com/2017/10/17/dariohealth-corp-drio-earns-news-sentiment-score-of-0-23.html.

About DarioHealth Corp.

DarioHealth Corp, formerly Labstyle Innovations Corp, is a digital health (mHealth) company. The Company is engaged in developing and commercializing a technology providing consumers with laboratory-testing capabilities using smart phones and other mobile devices. The Company’s product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with a pocket-sized, blood glucose monitoring device, Dario Smart Meter.

DarioHealth Corp. (DRIO) traded down 0.2541% during trading on Tuesday, hitting $1.8453. The stock had a trading volume of 6,787 shares. The firm has a 50 day moving average price of $1.83 and a 200-day moving average price of $1.83. DarioHealth Corp. has a 1-year low of $1.69 and a 1-year high of $4.70. The firm’s market capitalization is $18.00 million.

DarioHealth Corp. (NASDAQ:DRIO) last released its quarterly earnings results on Monday, August 14th. The company reported ($0.43) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.13). The business had revenue of $1.21 million during the quarter. DarioHealth Corp. had a negative return on equity of 626.32% and a negative net margin of 206.95%. On average, equities research analysts expect that DarioHealth Corp. will post ($0.62) EPS for the current year.

Separately, Aegis began coverage on DarioHealth Corp. in a research report on Tuesday, August 29th. They set a “buy” rating and a $3.50 price target on the stock.

COPYRIGHT VIOLATION WARNING: This piece was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://ledgergazette.com/2017/10/17/dariohealth-corp-drio-earns-news-sentiment-score-of-0-23.html.

About DarioHealth Corp.

DarioHealth Corp, formerly Labstyle Innovations Corp, is a digital health (mHealth) company. The Company is engaged in developing and commercializing a technology providing consumers with laboratory-testing capabilities using smart phones and other mobile devices. The Company’s product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with a pocket-sized, blood glucose monitoring device, Dario Smart Meter.

Insider Buying and Selling by Quarter for DarioHealth Corp. (NASDAQ:DRIO)

Receive News & Ratings for DarioHealth Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth Corp. and related companies with MarketBeat.com's FREE daily email newsletter.